Topics

CORRECTING and REPLACING Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)

20:15 EDT 1 May 2019 | Businesswire
This article has expired, however you can still download the PDF.
Preview:
Company to focus on benefits of CBD for non-addictive pain management and opioid, alcohol addiction recovery In the release dated April 30, 2019, the URL https://viverapharma.com in the 6th and 11th paragraphs has been chang...

Other Sources for this Article

Investor Relations and Canadian Media Enquiries:
ThinkHERO
Patrick Piette, CFA for Vivera Pharmaceuticals, Inc.
416-526-9911
investorrelations@viverapharma.com

U.S. Media Inquiries:
SRPR
Brenda Patterson for Vivera Pharmaceuticals, Inc.
949-667-1943
press@viverapharma.com

NEXT ARTICLE

More From BioPortfolio on "CORRECTING and REPLACING Vivera Pharmaceuticals Licenses TABMELT®, a Sublingual Pharmaceutical Drug-Delivery System for Cannabidiol (CBD)"

Quick Search

Relevant Topics

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...